Table 1

Presenting characteristics of patients with acquired hemophilia A

Characteristic (no. of patients for whom characteristic is known)No. of patients reported in 2-y study period for whom characteristic is known (%)
Age category (154) 
    1 to less than 16 y 1 (0.7) 
    16 to less than 65 y 22 (14.3) 
    65 to less than 85 y 97 (63.0) 
    85 y and older 34 (22.1) 
Underlying diagnosis (150) 
    None 95 (63.33) 
    Autoimmune or collagen vascular disease 25 (16.66) 
        Rheumatoid arthritis 9 (6.00) 
        Polymyalgia rheumatica 3 (2.00) 
        SLE 3 (2.00) 
        Other 10 (6.66) 
    Malignancy 22 (14.66) 
        Lung 5 (3.33) 
        Gastrointestinal 5 (3.33) 
        Prostate 3 (2.00) 
        Other 8 (5.33) 
    Dermatologic 5 (3.33) 
        Pemphigoid 3 (2.00) 
        Other 2 (1.33) 
    Pregnancy 3 (2.00) 
FVIII level category at diagnosis (154) 
    Severe, 1 IU/dL or less 46 (29.87) 
    Moderate, more than 1, less than 5 IU/dL 56 (36.36) 
    Mild, 5 or more, less than 50 IU/dL 52 (33.77) 
Inhibitor titer category at diagnosis (144) 
    0-10 BU/mL 9 (6.25) 
    11-100 BU/mL 119 (80.56) 
    101-1000 BU/mL 16 (11.11) 
Sex (122) 
    Female 70 (57.38) 
    Male 52 (42.62) 
Center type (172) 
    Comprehensive care hemophilia center 93 (54.07) 
    Hemophilia center 39 (22.67) 
    Nonhemophilia center 40 (23.26) 
Characteristic (no. of patients for whom characteristic is known)No. of patients reported in 2-y study period for whom characteristic is known (%)
Age category (154) 
    1 to less than 16 y 1 (0.7) 
    16 to less than 65 y 22 (14.3) 
    65 to less than 85 y 97 (63.0) 
    85 y and older 34 (22.1) 
Underlying diagnosis (150) 
    None 95 (63.33) 
    Autoimmune or collagen vascular disease 25 (16.66) 
        Rheumatoid arthritis 9 (6.00) 
        Polymyalgia rheumatica 3 (2.00) 
        SLE 3 (2.00) 
        Other 10 (6.66) 
    Malignancy 22 (14.66) 
        Lung 5 (3.33) 
        Gastrointestinal 5 (3.33) 
        Prostate 3 (2.00) 
        Other 8 (5.33) 
    Dermatologic 5 (3.33) 
        Pemphigoid 3 (2.00) 
        Other 2 (1.33) 
    Pregnancy 3 (2.00) 
FVIII level category at diagnosis (154) 
    Severe, 1 IU/dL or less 46 (29.87) 
    Moderate, more than 1, less than 5 IU/dL 56 (36.36) 
    Mild, 5 or more, less than 50 IU/dL 52 (33.77) 
Inhibitor titer category at diagnosis (144) 
    0-10 BU/mL 9 (6.25) 
    11-100 BU/mL 119 (80.56) 
    101-1000 BU/mL 16 (11.11) 
Sex (122) 
    Female 70 (57.38) 
    Male 52 (42.62) 
Center type (172) 
    Comprehensive care hemophilia center 93 (54.07) 
    Hemophilia center 39 (22.67) 
    Nonhemophilia center 40 (23.26) 

Each characteristic is shown as an absolute number and a percentage of the patients on whom data were known for that characteristic. Age-specific incidence per million UK population per year: 1-< 16 y, 0.045; 16-< 65 y, 0.29; 65-< 85 y, 5.97; 85 y and older, 14.66.

Close Modal

or Create an Account

Close Modal
Close Modal